ClinicalTrials.gg
Sign In
Not yet recruitingNCT07265817Updated Dec 5, 2025

Fecal Microbiota Transplantation for Decolonization of Multidrug-resistant Microorganisms

An interventional study of Fecal Microbial transplant Capsules and Placebo in Carbapenem-Resistant Enterobacteriaceae Colonization, sponsored by Kyungpook National University Hospital. Not yet recruiting. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-12-05.

Sponsored by Kyungpook National University Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

The aim of the study is to see whether fecal microbiota transplantation is effective to decolonize multidrug-resistant organisms.

02

Conditions studied

  • Carbapenem-Resistant Enterobacteriaceae Colonization
03

In context

Lead sponsor

Kyungpook National University Hospital is the lead sponsor of 80 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who have positive results in PCR or culture of rectal swab.

Exclusion criteria

Exclusion Criteria:

  • Not provide a consent.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Fecal microbiota transplantation group

    Combination Product: Fecal Microbial transplant Capsules

  • Placebo comparator
    Placebo

    Combination Product: Placebo

Interventions

  • Combination productFecal Microbial transplant Capsules

    3 pills per day for 3 consecutive days with placebo comparatator

  • Combination productPlacebo

    The same amount and shape capsules

06

What researchers measure

Primary outcomes

  1. Conversion to negative organism

    Time frame: 1 year

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2025; primary completion for Sep 2026, 9 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2025
First posted
Dec 5, 2025
StartEst.
Dec 1, 2025
Primary completionEst.
Sep 1, 2026
CompletionEst.
Oct 1, 2027
Last update
Dec 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07265817
Lead sponsor
Kyungpook National University Hospital
Responsible party
Eun Soo Kim, MD, PhD (Professor, Kyungpook National University Hospital) — Principal investigator
First posted
Dec 5, 2025
Start date
Dec 1, 2025 (estimated)
Primary completion
Sep 1, 2026 (estimated)
Completion
Oct 1, 2027 (estimated)
Last update
Dec 5, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Kyungpook National University Hospital

Start the discussion